neoadjuvant anti-PD-1

Phase 2Small molecule

neoadjuvant anti-PD-1 is one of 80 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

337 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

47 2

Gemzar

Johnson & Johnson

Phase 3

16 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

32 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

19 5

Taxotere

AAvyxa

Phase 3

19 6

Cyramza

Eli Lilly

Phase 3

4 7

Opdivo

Bristol-Myers Squibb

Phase 3

3 8

Ellence

Pfizer

Phase 3

3 9

DATROWAY

Daiichi Sankyo

Phase 3

1 10

Adrucil

EElorac, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Esophageal Squamous Cell Carcinoma

NCT06385730

Phase 2Not yet recruiting

Adenocarcinoma

NCT06469060

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)

Recruiting·SShanghai Chest Hospital·Phase 2·NCT06385730·60 enrolled

Adenocarcinoma1 trial

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction

Not yet recruiting·SShanghai Chest Hospital·Phase 2·NCT06469060·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for neoadjuvant anti-PD-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neoadjuvant anti-PD-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neoadjuvant anti-PD-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Chest Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Chest Hospital

neoadjuvant anti-PD-1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News